ANI Pharmaceuticals ANIP Rare Disease and Brands — Operating Income (Loss)

Other segment segments

Similar metrics at other companies

UUUURare Earth Elements Segment — Operating Income (Loss)

-$5.87M-62.4%

AMRXSpecialty — Operating Income (Loss)

$50.06M+234%

AMRXAffordable Medicines — Operating Income (Loss)

$120.94M+9.2%

RHRH — Operating Income

-$1.04M-102%

HRO

HROWBranded — Operating Income

-$11.63M-278%

KRYSReportable Segment — Operating Income (Loss)

$53.69M+48.1%

Questions, answered.

What is ANI Pharmaceuticals's rare disease and brands — operating income (loss)?

ANI Pharmaceuticals (ANIP) reported rare disease and brands — operating income (loss) of $36.25M in Q1 2026.

How has ANI Pharmaceuticals's rare disease and brands — operating income (loss) changed year-over-year?

ANI Pharmaceuticals's rare disease and brands — operating income (loss) increased by 71.5% year-over-year, from $21.13M to $36.25M.

What is the long-term trend for ANI Pharmaceuticals's rare disease and brands — operating income (loss)?

Over 3 years (2022 to 2025), ANI Pharmaceuticals's rare disease and brands — operating income (loss) has grown at a 137.5% compound annual growth rate (CAGR), from $10.54M to $141.24M.

What does rare disease and brands — operating income (loss) mean?

Measures the profitability of the Rare Disease and Brands segment by subtracting operating expenses from net revenues. It is a key performance indicator for evaluating the segment's ability to generate sustainable earnings from its core business activities.